Category Archives: FDA


Is There Any Reason to Allow Cigarette Companies to Send Coupons (or Any Other Advertising) to Nonsmokers?






  A recent study in the Nicotine & Tobacco Research journal confirms that the tobacco industry sends discount cigarette coupons to non-smokers in the USA and that some of those receiving the coupons become smokers. The study concludes that its findings support more restrictive policies to curtail the use of tobacco product discount coupons because […]

Read More

Posted in FCTC, FDA, Tobacco, Uncategorized; Tagged: , , , , , , , , .


Louisiana Proposes that the Federal Government Bypass Patent Restrictions to Acquire Cheaper Hepatitis C Drugs






Anyone who follows U.S. public health issues – or who reads my blog posts – knows that the cost of the drugs needed to treat Hepatitis C infections is very high. The cost of these drugs is of particular concern to state health authorities who are charged with providing health care for Medicaid recipients and […]

Read More

Posted in FDA, National Healthcare, Uncategorized; Tagged: .


Direct to Consumer Genetic Testing: Risks and Opportunities






Accurate genetic testing stands to transform modern medicine by offering effective, personalized treatment. Last week, the U.S. Food and Drug Administration (FDA) authorized marketing of the first direct-to-consumer (DTC) genetic health risk (GHR) tests. Individuals in the US can now purchase DTC tests and gain potentially useful information on their genetic predisposition to 10 diseases […]

Read More

Posted in FDA, Non-communicable diseases;


FEDERAL TOBACCO CONTROL DURING THE TRUMP YEARS – AND TOBACCO PRODUCT INSERTS






Although the federal Tobacco Control Act gives the U.S. Food and Drug Agency extensive authorities to regulate tobacco products and their marketing, labeling, and sale, the Trump Administration’s new pro-business, anti-regulation approach might put some serious obstacles in the way of any significant new FDA regulations to reduce the massive amounts of tobacco use and […]

Read More

Posted in FDA, Tobacco; Tagged: , , , , , , , , , , .


Carfentanil






In an international game of Whac-A-Mol, this week China announced that it would be adding four lethal heroin-like narcotics to a list of controlled substances to help combat the growing opioid epidemic in America. The primary target of the ban is Carfentanil, one of the latest and deadliest synthetic opioids to show up in the […]

Read More

Posted in FDA, Global Health, Health reform, Trade, Uncategorized;


Archives

Stay Informed

Signup for our mailing list and stay up to date on the latest happenings at The O’Neill Institute

Or sign up for our RSS Feed

The views reflected in this blog are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.

See the full disclaimer and terms of use.